Neos Therapeutics, Inc. announced that Jerry McLaughlin has been appointed as Chief Executive Officer of Neos, effective June 27, 2018. He also will serve on the company's board of directors. Mr. McLaughlin joins Neos from AgeneBio, where he was President and Chief Executive Officer since June 2014.

Prior to joining AgeneBio, he served as the Senior Vice President and Chief Commercial Officer of NuPathe Inc. until the company was acquired by Teva Pharmaceuticals Industries Ltd. in 2014. Previously, Mr. McLaughlin was at Endo Pharmaceuticals from 2001 to 2007 and served in a variety of commercial leadership roles at Merck from 1990 to 2001. Mr. McLaughlin's appointment follows the mutual decision by Vipin K. Garg, Ph.D. and the Board of Directors for Dr. Garg to resign as Chief Executive Officer, President and Director of Neos.

Dr. Garg will serve as an advisor to the company through the end of July 2018 to assist with Mr. McLaughlin's transition.